Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

REFILE-TREASURIES-U.S. yields little changed on caution about stimulus package

Tue, 26th Jan 2021 15:48

(Fixes typo in U.S. Treasury 10-year yield to 1.03% in 7th
paragraph)
By Gertrude Chavez-Dreyfuss
NEW YORK, Jan 26 (Reuters) - U.S. Treasury yields were
little changed to slightly higher in choppy trading on Tuesday,
after hitting three-week lows on the long end of the curve, as
investors remained cautious in the near term about the size of a
proposed U.S. stimulus package as well as the slow global
roll-out of coronavirus vaccines.
The U.S yield curve steepened modestly after flattening on
Monday. The spread between U.S. two-year and 10-year yields
widened modestly to 91.50 basis points.
U.S. Senate Majority Leader Chuck Schumer said late on
Monday that he and his fellow Democrats may try to pass much of
President Joe Biden's $1.9 trillion coronavirus relief bill
using a process that would bypass a Republican filibuster and
could allow it to pass with a majority vote.
"We think ultimately it's going to be smaller than the $1.9
trillion," said Mike Chang, interest rates strategist at Citi in
New York. "We have penciled in around $600 billion-$1 trillion.
Timing is another issue, not just the size - how long it will
take to get the whole thing through."
In addition, there have been coronavirus vaccine delivery
problems globally, especially in Europe.
AstraZeneca, which developed its vaccine with Oxford
University, told the European Union that it could not meet
agreed supply targets by the end of March. Pfizer Inc
said there would be a temporary impact on shipments of its
vaccine in late January to early February.
In mid-morning trading, the U.S. benchmark 10-year yield
fell to 1.03%, from 1.04% late on Monday. It earlier
fell to 1.026%, its lowest level since Jan. 6.
U.S. 30-year yields slid to 1.7955% from
Monday's 1.799%, after earlier dropping to a three-week low of
1.786%.
U.S. 20-year bond yields also weakened to a
three-week trough and were last down at 1.59%.
On the front end of the curve, U.S. two-year yields slipped
to 0.121% from 0.127% on Monday.
Also on Tuesday, the Treasury auctions a record $61 billion
in 5-year notes after a solid 2-year debt sale on Monday.
"We believe there will be demand as the Treasury market has
had a firm tone in recent sessions," Justin Lederer, rates
strategist at Cantor Fitzgerald, said in a research note.
"We, however, would not be surprised by a small back-up
leading into 1 pm (bid deadline) and/or small tail as market
participants are cautious at the current yield levels, as the
sector is trading at its richest levels since early January and
12 basis points lower than its high yield print a few weeks
ago," he added.
Ahead of the auction, U.S. five-year note yields were little
changed at 0.4119%.

January 26 Tuesday 10:28AM New York / 1528 GMT
Price Current Net
Yield % Change
(bps)
Three-month bills 0.08 0.0811 0.000
Six-month bills 0.085 0.0862 -0.003
Two-year note 100-1/256 0.123 -0.004
Three-year note 99-214/256 0.1805 0.000
Five-year note 99-210/256 0.4119 0.002
Seven-year note 99-80/256 0.727 0.002
10-year note 98-116/256 1.0414 0.001
20-year bond 96-12/256 1.6089 0.005
30-year bond 95-236/256 1.8024 0.003

DOLLAR SWAP SPREADS
Last (bps) Net
Change
(bps)
U.S. 2-year dollar swap 7.50 -0.25
spread
U.S. 3-year dollar swap 8.25 0.25
spread
U.S. 5-year dollar swap 10.00 0.50
spread
U.S. 10-year dollar swap 3.25 0.25
spread
U.S. 30-year dollar swap -24.00 0.00
spread


(Reporting by Gertrude Chavez-Dreyfuss
Editing by Paul Simao)

More News
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more
30 Oct 2023 09:40

LONDON BROKER RATINGS: Jefferies cuts NatWest to underperform from buy

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
25 Oct 2023 11:04

PRESS: Soriot commits to five more years as AstraZeneca CEO - Times

(Alliance News) - Pascal Soriot has committed to remaining as chief executive officer of AstraZeneca PLC for another five years, The Times reported on Wednesday.

Read more
24 Oct 2023 17:08

LONDON MARKET CLOSE: FTSE 100 shakes off midday losses after US data

(Alliance News) - The FTSE 100 closed in the green on Tuesday following positive private sector data out of the US, despite figures closer to home showing a weaker UK private sector and rising unemployment.

Read more
24 Oct 2023 11:06

AstraZeneca says US accepts self-administered flu vaccine for review

(Alliance News) - AstraZeneca PLC on Tuesday said the US health watchdog has approved a review for its FluMist Quadrivalent self-administered flu vaccine, for which the drugmaker is seeking a green light.

Read more
23 Oct 2023 17:50

AstraZeneca celebrates drug trial results for cancer indications

(Alliance News) - AstraZeneca PLC on Monday said new drugs, developed in partnership with Daiichi Sankyo Co Ltd, showed positive results in patients with solid tumours, lung and breast cancer.

Read more
23 Oct 2023 17:08

LONDON MARKET CLOSE: Stocks largely down on Middle East hostilities

(Alliance News) - Stock prices in London closed largely lower on Monday, as investors were unable to shake off concerns surrounding the conflict in the Middle East, while developments in the US bond market added to the drama.

Read more
23 Oct 2023 08:45

TOP NEWS: AstraZeneca says Enhertu approved by European Commission

(Alliance News) - AstraZeneca PLC on Monday said its Enhertu treatment has been approved by the European Commission to treat adult lung cancer patients.

Read more
23 Oct 2023 07:46

LONDON BRIEFING: Keller expects higher profit; Upland rejects approach

(Alliance News) - Stocks in London are set to open slightly higher on Monday, as risk sentiment improves after a difficult period for markets last week.

Read more
18 Oct 2023 09:04

AstraZeneca drug Solaris approved in China as NMOSD treatment

(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder

Read more
17 Oct 2023 12:06

LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms

(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.